Evidence map›Paper›PMID 37849558›Full record

ArticleACS medicinal chemistry letters2023

Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M

Leon Jacobs, Aletta van der Westhuyzen, Nicole Pribut, Zackery W Dentmon, Dan Cui, Michael P D'Erasmo, Perry W Bartsch, Ken Liu, Robert M Cox, Sujay F Greenlund and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Novel Competitive, Nonpeptidic, SARS-CoV‑2 MACS medicinal chemistry letters · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Proof-of-concept studies with a computationally designed MProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Leon JacobsDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Aletta van der WesthuyzenDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Nicole PributDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.ORCID https://orcid.org/0000-0003-0439-9162
Zackery W DentmonDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Dan CuiCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, United States.
Michael P D'ErasmoDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Perry W BartschDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Ken LiuDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Robert M CoxCenter for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia 30303, United States.
Sujay F GreenlundCenter for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia 30303, United States.
Richard K PlemperCenter for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia 30303, United States.
Deborah MitchellEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.
Joshua MarlowEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.
Meghan K AndrewsEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.
Rebecca E KruegerEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.ORCID https://orcid.org/0000-0003-1962-7578
Zachary M SticherEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.
Alexander A KolykhalovEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.
Michael G NatchusEmory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.
Bin ZhouCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, United States.
Stephen C PellyDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.ORCID https://orcid.org/0000-0001-5930-4939
Dennis C LiottaDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.ORCID https://orcid.org/0000-0002-7736-7113

Funding

Project 6 - Development of Antivirals against AlphavirusesU19AI171403 · NIAID · EMORY UNIVERSITY · PI George Robert Painter, Richard K. Plemper · 2022 to 2026
$59.7M
NIAID NIH HHS U19 AI171403
6 · The paper itself

Abstract

The SARS-CoV-2 main protease (M

Identifiers

PMID37849558
PMCPMC10577883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.